<html>
<head>
</head>
<body>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;"><b>Nuvilex, Inc.’s Diabetes Study
May Get a Boost from Medical Marij. Research
</b></span></p>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;">In a recently published study in
the American Journal of Medicine, there might be something in
there that helps <b>Nuvilex, Inc.</b> (OTCQB: N V L
X) and its medical marij.
subsidiary, Medical Marij. Sciences, Inc. work
together to study Diabetes. Nuvilex has
been participating in a preclinical diabetes
study where the organization was able to
utilize its cell encapsulation technology to
basically create a kind of
“artificial pancreas” that
restrains blood sugar levels and
abolishes the need for insulin
treatment. </span></p>
<p><span style="font-size: small; font-family: arial, helvetica,
sans-serif;">The study named “The Impact of
Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults”
investigated the blo-od sugar-related
results of cannabis use amid
contributors in the National Health and Nutrition
Examination Survey from 2005 to 2010. With an increasing number
of states legalizing marij. for medicinal
purposes, research will become more
prevalent on the advantages of
cannabis, and Nuvilex’s branch should be right
in the mix.</span><br /><br /><span style="font-size: small; font-family:
arial, helvetica, sans-serif;">The use of research materials
issued by the auth.or is done at your own
risk. You are encouraged to do your own research before making any
investment decision with respect to the secu rity discussed
herein. The author has not been rewarded by any entity in connection with
the disbursement of these materials. You should
presume that as of the date of this report or letter, the author,
possibly along with or through our owners, affiliates, employees and/or
consultants, (communally referred to as the
author) has a position in all company shares (and/or options of the shares)
covered herein that is consistent with the position set forth in our
report. In connection with PLPL, the author has taken a long position.
Following the disbursement of any report or letter, the
author plans to continue engaging in trnsactns in the secu rity
covered herein, and we may be long, short, and/or neutral at any time
hereafter regardless of our initial position and we preserve the right to
procure or trade all or part of our position at any time without notice.
This practice could end in our trading securities at any time before,
during, and/or after the distribution of this
report. <a
href="http://cs.the-spout.com/link.php?M=6588707&N=235&L=3&F=H">Full
Disclaimer</a> </span><br /><br /><span style="font-size: small;
font-family: arial, helvetica, sans-serif;"><a
href="http://cs.the-spout.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=235">Unsubscribe <br
/><br /></a>100 N. 18th ST, Ste. 300,
Philadelphia, PA 19103 U.S.A.<a
href="http://cs.the-spout.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=235"><br
/></a></span></p>
<img
src="http://cs.the-spout.com/open.php?M=6588707&L=54&N=235&F=H&image=.jpg"
height="1" width="10"></body>
</html>